GlassScriptPhysician profile
Anna Shamsnia
NPI 1780188664
$922.31
in general payments reported to CMS, 2019-2025
16 companies · $104 in 2025
The $104 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $213 · 2024: $496 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $189.50 | 2022-2024 | Jornay Pm |
| Cranial Technologies, INC | $172.54 | 2023-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $153.67 | 2023-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $69.33 | 2022-2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $63.87 | 2024-2025 | |
| Corium, LLC | $42.51 | 2023-2024 | Azstarys |
| Pfizer INC. | $34.48 | 2023-2025 | |
| Seqirus USA INC | $33.59 | 2022-2024 | Flucelvax |
| Verrica Pharmaceuticals INC. | $32.54 | 2024 | Ycanth |
| Pharming Healthcare, INC. | $23.98 | 2023 | Ruconest |
| Merck Sharp & Dohme LLC | $22.43 | 2024 | Vaxelis, Vaxneuvance, M-M-R II |
| Kaleo, INC. | $21.35 | 2022 | |
| Sanofi Pasteur INC. | $19.66 | 2024 | |
| Sobi, INC | $15.32 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $13.54 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Shamsnia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.